2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
13
Ovarian Neoplasms
12
Neoplasms
12
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
6
Leukemia, Myeloid, Acute
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Solid Tumor
1
Sarcoma
1
Interventions
Injections
26
toripalimab
17
pembrolizumab
17
tislelizumab
12
Gemcitabine
8
Cisplatin
7
spartalizumab
6
atezolizumab
6
Irinotecan
6
Carboplatin
6
Paclitaxel
5
Oxaliplatin
5
Nivolumab
5
Leucovorin
5
Fluorouracil
5
camrelizumab
4
Pemetrexed
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
trastuzumab deruxtecan
3
sintilimab
3
olaparib
3
lenvatinib
3
cediranib
3
PM 01183
3
Drug Therapy
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
talazoparib
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts